Category: Accesswire

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that our President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast by Mr. Adam Torres. The interview video is available at https://youtu.be/nU_2dgd-u1g.

Mr. Torres began with asking what is the mission of NanoViricides. Dr. Diwan responded that NanoViricides was founded to revolutionize treatment of antiviral diseases the way penicillin revolutionized the treatment of bacterial infections.

Dr. Diwan explained the technology behind navoviricides drugs, and its completely different approach as compared to traditional antiviral drug development approaches.

Dr. Diwan explained the technology behind navoviricides drugs, and its completely different approach as compared to traditional antiviral drug development approaches. Dr. Diwan explained that this different approach provides several important benefits –

• Viruses cannot escape a nanoviricide drug – because the nanoviricide copies the essential host-side features that the virus uses to cause cell infection, and these do not change no matter how much the virus changes. This is unlike vaccines, antibodies, and traditional small chemical drugs that are all escaped by viruses as they change under pressure.

• Irrespective of patient immune status, a nanoviricide drug is expected to work, because a nanoviricide does not depend upon the patient’s immune system. In contrast, vaccines require competent immune system to produce effect. Antibodies also require competent immune system that must recognize the virus-antibody complexes and act upon them. In a severe viral infection, the patient’s immune system is often derailed by the virus. Additionally, immunoicompromised patient population is increasing due to increase in chronic diseases such as obesity, diabetes, allergies, as well as infectious diseases such as HIV, EBV and others.

• All of the patient population, potentially from infants to adults to geriatrics, would be eligible for treatment with NV-387, because of its excellent safety and tolerability profile resulting from design using biocompatible, biodegradable components.

Dr. Diwan explained that the Company’s drug candidate NV-387 has demonstrated efficacy against a number of unrelated viruses in animal models. Thus the goal of developing an emperic therapy for the treatment of acute respiratory infections is now within reach, with continuing clinical advancement.

Dr. Diwan explained that NV-387 had shown excellent effectiveness in lethal animal models of infections of viruses including Influenza, RSV, Coronaviruses, MPox, Smallpox as well as Measles. In fact NV-387 treatment led to complete cure of RSV infection in lethally infected animals. Additionally, NV-387 was found to be substantially superior to existing influenza therapeutics, namely Tamiflu (oselatmivir) and Xofluza (baloxavir) in a lethal infection animal model.

There is no approved therapy for MPox. Two drugs approved under the US FDA “Animal Rule” process, namely tecovirimat and brincidofovir were put into clinical trials for treatment of MPox. Tecovirimat failed to show improvement over the standard of care. Brincidofovir was dosed in an initial cohort in January, 2025 but no data can be found about its effects, and the clinical trial does not appear to have advanced further. Previously, in three MPox cases treated in the UK under emergency use protocols, brincidofovir led to significant elevation of liver enzymes and the drug was discontinued. No efficacy signal was found in these three cases.

There is no approved therapy for treatment of RSV infection, other than the toxic ribavirin as a last resort. Three antibodies have been approved for treatment of newborns so that they would not come down with RSV infection. A vaccine has been approved for treatment of expectant mothers despite risk of early/preterm births. These approvals indicate the severity of the problem and the need for an actual treatment of RSV infection.

There is no approved treatment for Measles virus infection.

Dr. Diwan advised that NV-387 has completed Phase I clinical trial in healthy subjects with no reported adverse events. He further stated that a Phase II clinical trial to test NV-387 for efficacy against Mpox (Monkeypox) virus is ready to begin soon. The ACOREP regulatory agency of the Democratic Republic of Congo (DRC) has already given permission for the clinical trial. The clinical trial application process has been completed. The trial is expected to begin with dosing of the first cohort of patients once the clinical site preparations are completed.

NV-387 is estimated to address a market potential of over $17 Billion by 2030 if approved, based on its broad spectrum and multiple indications.

Mr. Torres closed with advising the audience that Anil will be presenting and will be available for meetings at the Dealflow Discovery Conference at the Borgata Hotel in New Jersey on January 28th and 29th. Subsequent to the Conference, Dr. Diwan now happily notes that he had several successful meetings at this Conference.

ABOUT MISSION MATTERS

Mission Matters media is a platform designed to amplify and give voice to the stories of entrepreneurs, entertainers, enterprises, executives and experts. Our catalogue of 100,000+ shows, media, podcasts, and books tell meaningful stories that will inspire current and future generations. We unveil tomorrow’s narratives today.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide^™ class of drug candidates and the nanoviricide^™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

KELOWNA, BC / ACCESS Newswire / February 2, 2026 / Career City College has been recognized with the 2025 Consumer Choice Award in the category of School – Career & Business for the Kelowna region. This distinction highlights the college’s commitment to delivering accessible, high-quality education that equips learners across Canada with the skills and confidence to succeed in their chosen careers.

Founded on the belief that education should fit into students’ lives, not the other way around, Career City College is a fully online, accredited institution offering flexible diploma and certificate programs in areas such as accounting, bookkeeping, digital marketing, hospitality, human resources, and medical office administration. Designed to reflect the evolving needs of today’s workforce, each program provides practical, hands-on training and one-on-one instructor support to ensure students are job-ready upon graduation.

Flexible Learning for Real-World Success

At the heart of Career City College’s approach is a dedication to student-centred learning. With monthly start dates, learners can begin their studies when it suits them best, removing barriers that often prevent individuals from advancing their education. Every student benefits from personalized mentorship, connecting directly with instructors who bring real-world experience and industry insight to every lesson.

This combination of flexibility and individual support has made Career City College a trusted choice for working professionals, newcomers, and students balancing education with personal or family commitments. Whether pursuing a career change or professional advancement, students find programs tailored to real-world outcomes, helping them build the skills employers value most.

Empowering Students Across Canada

Though headquartered in Kelowna, Career City College serves learners nationwide through its interactive online platform. The college’s mission extends beyond academics, focusing on empowering individuals to achieve personal and professional growth through meaningful education. Each course is structured to blend theoretical knowledge with practical applications, ensuring graduates can immediately apply what they learn in the workplace.

“Our mission has always been to help students reach their career goals by providing flexible, practical, and industry-relevant education,” says Jag Basran, Chief Executive Officer at Career City College. “Receiving the Consumer Choice Award is a tremendous honour that reinforces our commitment to creating accessible learning opportunities for students across Canada. It is also a reflection of our incredible team and the success stories of our graduates, who inspire us every day.”

A Trusted Name in Career Education

Accredited by respected educational authorities, Career City College upholds rigorous standards of academic quality and professional ethics. The college’s success is measured not just by enrolment numbers but by the achievements of its graduates, many of whom have gone on to build rewarding careers in business, healthcare, and technology sectors.

The recognition from Consumer Choice Award underscores Career City College’s growing reputation as one of Canada’s leading online institutions for career and business education. By combining accessibility, innovation, and individualized support, the college continues to set a new standard for distance learning in Canada.

For more information about programs and enrolment, visit www.careercitycollege.ca or CLICK HERE

About Career City College
Career City College is a fully online, accredited post-secondary institution based in Kelowna, British Columbia. The college offers diploma and certificate programs in career-focused fields including accounting, digital marketing, hospitality, human resources, and medical office administration. With flexible monthly intakes and personalized one-on-one instructor support, Career City College is committed to helping students gain the practical skills and confidence needed to succeed in today’s evolving job market.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognizing and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Expanded role reflects operational scale and execution across U.S. manufacturing

ORLANDO, FLORIDA / ACCESS Newswire / February 2, 2026 / Unusual Machines today announced the promotion of Drew Camden to President, effective immediately. Camden will continue to serve as Chief Operating Officer, maintaining responsibility for manufacturing, supply chain, and operational execution across the Company.

Since joining Unusual Machines, Camden has led the expansion of U.S.-based manufacturing, including domestic motor production and increased drone assembly capacity. During this period, the Company has brought additional facilities online, improved throughput, and strengthened coordination across manufacturing, supply chain, and fulfillment to support growing enterprise and defense demand.

“As we grow and provide products that are critical to our customers, it’s important that we recognize the Company is bigger than any one person and build continuity,” said Allan Evans, Chief Executive Officer of Unusual Machines. “Drew is a demonstrated leader who has led the most execution-critical parts of our business. More importantly, he brings the attitude and approach that embody what Unusual Machines stands for. I look forward to continuing to work side by side with him as we keep building.”

“Our focus is on moving programs from intent to execution,” said Drew Camden, President and Chief Operating Officer of Unusual Machines. “As we rapidly scale the company, my role is to make sure our operations keep pace with the company’s direction so customers can continue to rely on us.”

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit unusualmachines.com.

Investor Contact:
CS Investor Relations
investors@unusualmachines.com

Media Contact:
media@unusualmachines.com

SOURCE: Unusual Machines, Inc.

View the original press release on ACCESS Newswire

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025.

MIAMI, FL / ACCESS Newswire / February 2, 2026 / Digi Power X Inc. (“Digipower X” or the “Company“) (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company’s expansion strategy.

Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon’s first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.

Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.

Mr. Vestberg’s appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets.

“Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions,” said Michel Amar, Chairman and Chief Executive Officer of Digipower X. “He understands what most of the market overlooks: AI’s bottleneck isn’t algorithms or chips, it’s power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.”

“I’ve spent over 30 years building the networks that move data,” said Mr. Vestberg. “The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach.”

Infrastructure Experience Aligned with AI Scale

During his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.

Mr. Vestberg insightfully noted at Davos 2024 that “one of the most important infrastructures of this century is digital infrastructure,” and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.

Mr. Vestberg currently serves as a board member of BlackRock and Verizon.

Addressing the Power and Deployment Constraint in AI Infrastructure

Digipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.

In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment.

“Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed,” said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. “His experience aligns directly with Digipower X’s mission to deliver infrastructure at the scale and speed this market now requires.”

Vestberg’s Strategic Focus

In his advisory role, Mr. Vestberg will work closely with Digipower X’s executive team on:

• AI infrastructure deployment strategy and scaling frameworks;

• Distributed and edge-compute architectures for inference-driven workloads;

• Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;

• Power optimization and energy-efficient data center design;

• Tier-3 redundancy and mission-critical reliability standards; and

• International expansion strategy and site prioritization.

About Digipower X

Digipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.

For further information, please contact:

Michel Amar, Chief Executive Officer
Digipower X Inc.
www.digipowerx.com

Investor Relations
T: 888-474-9222
Email: IR@digihostpower.com

Cautionary Statement

Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Except for the statements of historical fact, this news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company’s expectations concerning the potential contributions by our new advisor to the Company’s strategic efforts, the potential further improvements to profitability and efficiency across the Company’s operations, including, as a result of the Company’s expansion efforts, potential for the Company’s long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company’s operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company’s filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company’s assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company’s normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.

SOURCE: Digi Power X Inc.

View the original press release on ACCESS Newswire

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / February 2, 2026 / ILIA English Academy, a trusted leader in online language education, wins the 2025 Consumer Choice Award in the Language Schools category for the Vancouver region. This recognition reflects ILIA’s outstanding reputation for delivering high-quality instruction in English, French, and Spanish to students across Canada and around the world.

Founded on over 30 years of professional experience, ILIA English Academy provides flexible, comprehensive language programs taught by certified instructors located in Vancouver, Toronto, Montreal, Calgary, and Costa Rica. Whether preparing for official exams like IELTS or CELPIP, or simply improving fluency in a new language, ILIA equips students with the skills and confidence needed to succeed.

Online Language Training Backed by Expertise

ILIA English Academy has become a trusted destination for students seeking academic and career advancement through language mastery. As a CELPIP Official Network Member and an IELTS Information and Registration Centre in Vancouver, the academy offers a full suite of services, including training classes, personalized tutoring, and mock exams.

“Our mission has always been to make language education accessible, engaging, and effective,” says the ILIA English Academy team. “We’re honoured by this award, which reinforces the trust students place in us to help them achieve their goals.”

Global Reach, Local Excellence

ILIA’s online model enables it to serve a global audience while remaining deeply connected to the Vancouver community. The academy has supported thousands of students from all walks of life-immigrants preparing for Canadian language benchmarks, professionals expanding their international communication skills, and learners pursuing personal enrichment.

With instructors fluent in multiple languages and trained in evidence-based pedagogy, ILIA tailors every class to individual learning styles and goals.

Courses for Every Need

ILIA offers a wide range of programs, including:

• IELTS and CELPIP preparation: Tailored exam-focused training with practice tests and feedback.

• ESL (English as a Second Language): For beginners to advanced speakers.

• French and Spanish instruction: Conversational and academic programs taught by native speakers.

• Mock exams and assessments: Realistic practice experiences to boost student readiness.

All courses are delivered through user-friendly online platforms, with flexible scheduling options to accommodate busy professionals and international time zones.

Award-Winning Commitment to Student Success

Consumer Choice Award is North America’s most trusted mark of business excellence, based on third-party research and brand reputation analysis in each region. For ILIA, this recognition underscores their ongoing efforts to deliver quality education and build lasting relationships with students.

“We are incredibly proud of this award because it’s a reflection of the impact we’ve had on our learners’ lives,” says the ILIA team. “It inspires us to keep innovating, improving, and ensuring our students succeed.”

A Community of Passionate Educators

ILIA’s strength lies in its people. From highly trained educators to responsive support staff, the academy is built on a shared commitment to helping students thrive.

“We’re more than a school-we’re a community,” the team notes. “We believe in fostering a supportive environment where learners feel empowered and valued.”

To learn more about ILIA English Academy’s award-winning programs, or to register for classes and mock exams, visit iliaenglish.ca or explore their Consumer Choice Award profile here.

About ILIA English Academy
ILIA English Academy is an online language school offering IELTS, CELPIP, ESL, French, and Spanish programs to students around the world. With over 30 years of teaching experience, ILIA provides accessible, high-quality education designed to help students meet personal, academic, and professional goals. The school is a CELPIP Official Network Member and an IELTS Information & Registration Centre based in Vancouver.

About Consumer Choice Award
Consumer Choice Award has been recognizing business excellence in North America since 1987. Winners are determined through a rigorous research process that gathers feedback from consumers and evaluates brand reputation and customer satisfaction. Visit www.ccaward.com to learn more.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

CALGARY, AB / ACCESS Newswire / February 2, 2026 / The Audio Room Ltd., Calgary’s destination for high-performance audio and custom home theatre solutions, has been recognised with the 2025 Consumer Choice Award in the Home Theatre Systems category for Southern Alberta. This recognition marks an important milestone for the company, which has been serving music lovers and home entertainment enthusiasts for more than 30 years.

Founded with a passion for sound and picture quality, The Audio Room Ltd. is committed to helping clients create immersive audio-visual experiences that reflect the artist’s true intent. Whether it’s through world-class speakers, advanced streaming systems, or full-scale custom home theatre installations, the team works to deliver exceptional results for every project.

Crafting Immersive Experiences

From wireless systems and turntables to high-performance headphones and full-scale theatre design, The Audio Room Ltd. offers a curated selection of products and services that bring entertainment spaces to life. Every system is designed with precision and a deep understanding of how sound and visuals can transform a room.

“For more than three decades, our goal has been to deliver experiences that go beyond equipment,” says the team at The Audio Room Ltd. “This award is a reflection of the trust our customers place in us and the relationships we’ve built in the community.”

Recognition Rooted in Customer Trust

The Consumer Choice Award is determined by independent research that evaluates reputation, customer satisfaction, and overall business excellence. Being selected as Southern Alberta’s top home theatre systems provider demonstrates The Audio Room Ltd.’s continued commitment to quality and client satisfaction.

“We’re honoured to be recognised by the community we’ve proudly served for so many years,” the team adds. “It’s inspiring to know that our dedication to craftsmanship and service continues to resonate with our clients.”

Three Decades of Excellence

Since opening its doors, The Audio Room Ltd. has earned a reputation as a trusted expert in the home theatre and audio industry. The company’s experienced team brings technical knowledge, creativity, and a passion for innovation to every installation, ensuring customers receive solutions tailored to their lifestyle and entertainment goals.

Whether upgrading a simple listening room or designing a state-of-the-art home cinema, The Audio Room Ltd. continues to raise the bar for home entertainment across Calgary and Southern Alberta.

Continuing A Legacy of Sound

As The Audio Room Ltd. celebrates its recognition with the 2025 Consumer Choice Award, the company remains focused on its mission: to create experiences that allow people to truly hear and feel music and film the way they were meant to be enjoyed.

To learn more about The Audio Room Ltd. or to explore its products and services, visit www.theaudioroom.ca or CLICK HERE.

About The Audio Room Ltd.
For over 30 years, The Audio Room Ltd. has specialised in high-performance audio products and custom home theatre installations in Calgary and Southern Alberta. The company offers a curated range of speakers, components, turntables, streaming systems, wireless systems, and headphones, alongside expert design and installation services. Its mission is to deliver immersive entertainment experiences that capture the artist’s intent. Learn more at www.theaudioroom.ca.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire